SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

April 23, 2013 07:00 ET

Summit NW Selects Implant Sciences' QS-B220 Trace Detection System for Air Cargo Screening

WILMINGTON, MA--(Marketwired - Apr 23, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has sold its Quantum Sniffer™ QS-B220 desktop explosives trace detector to Summit NW Corporation. Summit NW, a Portland, Oregon-based trucking company in the northwest with Certified Cargo Screening Facility (CCSF) operations will use the QS-B220 for air cargo screening in its new facility.

Having recently seen the QS-B220 demonstrated at the AirCargo 2013 conference in Las Vegas last month, Summit NW was impressed with its performance and quickly reached a purchase decision. The QS-B220 was approved for air cargo screening by the Transportation Security Administration in January 2013.

Sabine Morris, Vice President of Operations at Summit NW commented, "The QS-B220 offers an impressive combination of advanced technology such as automatic internal calibration, ease-of-use, and low total cost of ownership. Everything we've seen shows that it will be operationally superior to our existing systems. Deploying it in the new facility for our explosives trace detection needs was simply a better business decision."

"The AirCargo conference was our opportunity to showcase the QS-B220 just after having received TSA approval. We received a tremendous amount of interest at the conference, which is now starting to translate into sales. We look forward to working with Summit NW and serving their growing needs," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones.

About the Quantum Sniffer™ QS-B220 Desktop Explosives Trace Detector

The TSA approved Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, as well as drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and internal automatic self-calibration, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to receive product approval from the US Transportation Security Administration. Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:

    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact